Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PECATI: Pembrolizumab and Lenvatinib in Pre-Treated Thymic Carcinoma
NCT04710628Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Sep 2021
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in thymic carcinoma (TC), Thymoma type B3 (B3), sponsored by MEDSIR. Started Sep 2021; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
thymic carcinoma (TC)Thymoma type B3 (B3)
Beyond the preview
Go deeper on NCT04710628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710628.